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Abstract
Data from clinical trials are needed to guide the safe and
effective use of medicines in children. Clinical trials are
challenging to design and implement in all populations,
and children present additional considerations. Several
regions including the UK, USA and Europe have established
clinical trial infrastructure to capitalise on expertise
and promote clinical trials enrolling children. Our
objective is to describe the partnerships and operational
considerations for the development of paediatric clinical
trials infrastructure in Canada. We describe the design
and conduct of four emergency room paediatric trials,
with four separate sponsors, across four provinces in
parallel. Operations discussed include multisite contract
development, centralised risk-based data monitoring,
ethical review and patient engagement. We conclude
with lessons learnt, additional challenges and potential
solutions to facilitate drug development for children in
Canada.

Introduction
Due to the historical exclusion of children
from clinical drug trials, paediatric healthcare providers have only minimal safety
and effectiveness data to guide their daily
prescribing practices. More than 50% of children in Canada require at least one prescription medication each year.1 Off-label drug
use (ie, without regulatory authorisation
based on direct empirical evidence from clinical trials) is commonplace and may lead to
over- or under-dosing of children, carrying
the inherent risks of adverse drug reactions
and suboptimal clinical effectiveness. Critical
issues influencing the development and evaluation of medicines for children in Canada
were summarised as the following key findings, quoted from an expert panel report
released by the Council of Canadian Academies in 20142:
i. Children take medications, many of
which have not been proven safe and effective for their use;

ii. Children respond to medications differently from adults; thus, medications must
be studied in children and formulated
for children;
iii. Studying medicines in children is always
possible and in their best interests;
iv. In the USA and Europe, paediatric medicines research is encouraged, required
and monitored in ways that offer lessons
for Canada; and
v. Paediatric medicines research is a
Canadian strength, but it requires reinforcement and sustained capacity and
infrastructure to realise its full potential.
Several economical, ethical and logistical
challenges specific to conducting clinical
trials for children have contributed to gaps in
the current evidence base for the use of medicines in children.1 3 Given that most of the
drugs in question have already been developed and licensed for use in adults, there is a
notable lack of industry incentive to organise
or fund trials in children. This places the
financial burden of very expensive research
squarely on government and not-for-profit
agencies, academic institutions and clinical
investigators, who have access to comparably less, and highly competitive, funding.
Compounding this is the relative infrequency
of many serious childhood illnesses, making
it difficult to answer most research questions
through enrolling participants at a single
centre. To recruit a sufficient number of
participants in a timely fashion, paediatric
clinical trials usually involve multiple sites,
resulting in considerable complexity in negotiating larger budgets, establishing contracts
and data sharing agreements and carrying
out multiple institutional ethics reviews.4
In April 2016, the Canadian Institutes
of Health Research launched the ‘Strategy
for Patient-Oriented Research innovative
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Canada. The intended outcome of the iPCT project is to
finish these trials with established infrastructure that will
not only have assisted the PERC network and built new
knowledge in paediatric emergency medicine, but will
also endure and expand, at least as proof of principle, to
allow KidsCAN Trials to support drug trials in all areas of
paediatric medicine. This article aims to summarise the
innovative approaches taken in trial management and
data coordination to maximise the return on investment
in these four investigator-led clinical trials conducted in
parallel across six Canadian paediatric health centres.
While centralised statistical and decision-making analyses are also part of the project goals described above,
the outcomes of the iPCT project in this regard have yet
to be finalised and as such will be presented in a subsequent article when available. Here, we describe the key
partnerships and the centralised structures and activities
that form the foundation for this initiative: centralised
management, centralised risk-based safety monitoring,
ethical review and patient engagement. We follow with a
discussion of challenges and solutions and conclude with
our key messages.
Partnerships
The iPCT project emerged from, and is supported by,
extensive partnerships among existing organisations.
This has allowed us to capitalise on existing local paediatric clinical research infrastructure in Canada, to facilitate launching of this project (see figure 1 and Related
Links for more information).
KidsCAN trials
KidsCAN Trials was established in 2016 and is a national
hub to coordinate research, training and knowledge
transfer in the safe therapeutic use of medicines for children. By bringing together academic child health centres
and their affiliated research institutes, KidsCAN Trials
encourages the uptake of new clinical trial methods and

Figure 1 Partner organisations in the formation and operation of the iPCT project network. Partnerships comprise academic,
not-for-profit and government organisations across provincial jurisdictions. The role of each organisation listed is described in
the text. CHI, George and Fay Yee Centre for Healthcare Innovation; CHRIM, Children’s Hospital Research Institute of Manitoba;
DCC, data coordinating centre; iPCT, Innovation in Paediatric Clinical Trials; MC, methods core; MICYRN, Maternal, Infant, Child
and Youth Research Network; NCC, network coordinating centre; PERC, Paediatric Emergency Research Network Canada;
TREKK, Translating Emergency Knowledge for Kids; WCHRI, Women and Children’s Health Research Institute.
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Clinical Trials Initiative’ to increase Canada’s competitiveness in clinical trial research, stimulate adoption of
novel trial methodologies and build capacity for innovative clinical trials (see Related Links for more information). Recognising the need for national infrastructure
to address the challenges listed above, as well as the
need to improve trial design to adequately inform decision-making, a team of Canadian paediatric investigators
was successful in securing funds for a multi-year project
entitled ‘Innovation in Paediatric Clinical Trials (iPCT)”.
The binary aim of the iPCT project is to demonstrate that
both methodological innovation and efficiencies through
centralised data management and trial coordination will
allow the generation of evidence that will have an immediate impact on paediatric clinical decision-making.
The iPCT project is the initiative of a nascent, national
paediatric clinical trial network known as KidsCAN Trials
(see Related Links for more information). In seeking
to build, test and establish national infrastructure to
conduct paediatric clinical trials in Canada, the KidsCAN
Trials steering committee engaged a well-established
national research network in paediatric emergency medicine, Paediatric Emergency Research Canada (PERC)
for collaboration.5 Four specific clinical trials, led by
four experienced clinician-scientists in paediatric emergency medicine, were chosen to create an environment
in which several innovative approaches to conducting
paediatric clinical trials could be tested. These four trials
themselves have intrinsic research value for paediatric
emergency medicine and reflect conditions or procedures
commonly encountered in the paediatric emergency
department: bronchiolitis, musculoskeletal injuries,
procedural sedation and acute gastroenteritis. Beyond
the empirical results of each trial, however, lies the synergistic value of conducting four multicentre clinical trials
in parallel. There are financial challenges for investigators to engage a Contract Research Organization (CRO)
and there are limited options with paediatric expertise in

Open access

Paediatric emergency research Canada
PERC was established in 1995 with the aim of conducting
research to improve outcomes in children brought to
the emergency department for acute care.6 At the time
of writing, PERC has 21 ongoing studies, 11 of which are
clinical trials, and has received more than $39 million in
research grant funding. PERC’s membership includes
physicians, nurses, research managers, coordinators and
postgraduate trainees from across Canada.
Translating emergency knowledge for kids
Translating Emergency Knowledge for Kids (TREKK) is
a Canadian knowledge mobilisation network focused on
developing and disseminating evidence-based tools and
resources for caregivers and clinicians. TREKK’s parent
advisory group has been central to the iPCT project in
proving feedback on study design and the development
of the assent form described under ‘Ethical Review’
below. TREKK’s central administration is located in
Winnipeg.
Maternal infant child youth research network
Maternal, Infant, Child and Youth Research Network
(MICYRN) is a federal not-for-profit, charitable organisation founded in 2006 to build capacity for highquality applied health research. It links 20 maternal and
child health research organisations across Canada and
provides support to new and emerging teams. MICYRN
and KidsCAN Trials are leading the research ethics board
harmonisation initiatives and fostering national collaboration among patients, families, child healthcare institutions, researchers, educators and regulators.
Children’s hospital research institute of Manitoba
Children’s Hospital Research Institute of Manitoba
(CHRIM) is supported by the Children’s Hospital Foundation of Manitoba and collaborates with partner organisations to facilitate innovative research activities focused
on improving the health of children. CHRIM hosts the
Network Coordinating Centre for the iPCT project, in
Winnipeg.
George and Fay Yee centre for healthcare innovation
George and Fay Yee Centre for Healthcare Innovation
(CHI) is a partnership between the University of Manitoba and the Winnipeg Regional Health Authority. It
provides seven platforms which offer research expertise
and services to facilitate development and implementation of evidence-based patient engagement initiatives. As
part of the iPCT project, the CHI is providing training
and consultation in patient engagement. In addition, it
will lead the development of an online portal to share
templates as well as training and educational resources
for paediatric clinical trials.
Kelly LE, et al. BMJ Open 2019;9:e029024. doi:10.1136/bmjopen-2019-029024

Women and children’s health research institute
Women and Children’s Health Research Institute
(WCHRI), located in Edmonton, Alberta, is supported by
the Stollery Children’s Hospital and the Royal Alexandra
Hospital Foundation in partnership with the University
of Alberta and Alberta Health Services to improve the
lives of women and children through research. The Data
Coordinating Centre, located at WCHRI, supports the
data management needs of this and other child health
research networks. The Quality Management in Clinical
Research department at the University of Alberta serves
to meet the regulatory requirements of the university in
the conduct of clinical trials through quality management
and trial monitoring.
The hospital for sick children (SickKids) research institute
Located in Toronto, this research institute is supported
by the SickKids Foundation and collaborates with partner
organisations to facilitate innovative research activities
focused on improving the health of children. Clinical
trial methodologists based here, within the Child Health
Evaluative Sciences Programme lead the Methods Core
for the iPCT project, as described below.
Centralised management
Our iPCT network consists of several trial-specific nodes
of coordination operating in partnership with a central
network coordinating centre (NCC), data coordinating
centre (DCC) and a methods core (MC) (figure 2). This
structure was established to provide the four clinical
trials with support similar to that of a Contract Research
Organisation. The iPCT steering committee includes
the NCC, DCC, MC, the principal investigators and trial
managers for each of the four trials, the TREKK parent
advisory group and a parent partner. These newly-formed
centralised structures are able to leverage the existing
research infrastructure in the emergency departments
of the six enrolling sites. These sites have significant and
collective experience in conducting multicentre, investigator-initiated clinical trials.
Network coordinating centre
Members of the network coordinating centre (NCC)
include the network manager, two paediatricians experienced in clinical trials, a methodologist, a project manager
and an administrative coordinator. The NCC meets
weekly and is responsible for overseeing the operation of
all four clinical trials, including study budgets, training,
chairing the steering committee and financial reporting
to funding organisations. The NCC is also responsible for
the development of standardised templates for protocol
writing, start-up training for each study, adverse drug reaction reporting, training logs and data clarification forms.
The legal team at the NCC, in collaboration with
legal representation from each participating institution
(ie, recruitment site), created a master contract which
outlines a partnership arrangement between the participating institutions (figure 3). In addition to the network
3
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agreement, a template clinical trial agreement was
drafted by the NCC to be used to generate individual trial
agreements. These vary slightly based on the institutional
policies of the four sponsoring research institutes (one
for each trial), but each trial agreement outlines conduct
and responsibilities specific to the trial hosted at the site.
A further key role for the NCC is the establishment
of a centralised Data Safety Monitoring Board (DSMB)
with the goal of providing a comprehensive review of
study data for all four trials using only one committee,
to enhance efficiency. The NCC developed a charter for
the DSMB outlining roles and responsibilities, membership, review process and meeting structure. The DCC
(described below) provides extensive reporting to the
DSMB regarding approach, recruitment and retention for
all four studies, as well as specific safety issues regarding
procedures and medications, if any. Patient recruitment
will be measured against estimated recruitment numbers

needed from the study protocol based on power calculations provided by principal investigators. Over time, the
DSMB will advise the iPCT steering committee regarding
the merit of continuation of studies based on recruitment
and any arising safety concerns. The charter is a living
document and can be adapted as needed by the DSMB in
conjunction with the iPCT steering committee.
Data coordinating centre
The data coordinating centre (DCC) includes a biostatistician, data scientist, data manager, database developers
and team lead for overall project management. The DCC
is responsible for the development and support of the
clinical trial databases using the electronic data capture
tool, REDCap,7 for data management, maintenance of
the database infrastructure, development and execution of the data management plan, data reporting and
query management. In addition, the DCC is supporting

Figure 3 Contents of overarching network agreement and individual clinical trial agreements for the iPCT project. iPCT,
Innovation in Paediatric Clinical Trials.

4

Kelly LE, et al. BMJ Open 2019;9:e029024. doi:10.1136/bmjopen-2019-029024

BMJ Open: first published as 10.1136/bmjopen-2019-029024 on 27 June 2019. Downloaded from http://bmjopen.bmj.com/ on July 4, 2022 by guest. Protected by copyright.

Figure 2 Geographical distribution of the iPCT project network across Canada. Four sponsoring institutions (yellow stars), one
for each trial, coordinate across six primary recruitment centres (black text) with the NCC in Winnipeg, the DCC in Edmonton
and the MC in Toronto. CHRIM, Children’s Hospital Research Institute of Manitoba; CHU, Centre hospitalier universitaire;
DCC, data coordinating centre; iPCT, Innovation in Paediatric Clinical Trials; MC, methods core, NCC, network coordinating
centre; WCRHI, Women and Children’s Health Research Institute.
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Methods core
The methods core (MC) comprises experts across three
institutions and includes two trial methodologists, two
health economists, three biostatisticians and a project
manager. The MC has supported the trials’ protocol
development and leads the development of innovation
methodology in trial design and statistical analysis for
all four trials. Over the coming months, the MC will also
develop training modules on aspects of innovative trial
design and will be responsible for any interim analyses as
well as the final data analysis for each trial. Some innovative methods being applied include the incorporation
of Bayesian decision analyses and value of information
analysis in trial design, as well as the use of innovative
randomisation designs and patient preference elicitation methods in understanding which outcomes are most
important to patients, parents, healthcare providers and
policy-makers in a clinical trial. The latter is described in
more detail under ‘Patient engagement’ below.
Coordinated operations
The extensive costs of implementing a multicentre drug
trial may jeopardise the execution of a high quality study
design (ie, compromising to the quality of the data collection or extent of new knowledge achieved as a result of
incomplete data accrual). With the goal of eliminating
the need for such compromises, our model is intended
to significantly reduce costs by (i) initiating four clinical
trials over 4 years with overlapping recruitment periods
and (ii) avoiding duplication within the sampling frames.
Patient arrival in a paediatric emergency department is
rarely predicted or planned. Thus, anticipating staffing
needs for recruitment of children arriving with a specific
medical condition is virtually impossible. Instead, emergency researchers schedule research nurses to match to
high volume times in the emergency department. The
cost of recruitment personnel is by far the largest budget
item in most paediatric drug trials. By sharing this expenditure across four studies, we can reduce the per-patient
cost of recruitment by optimising the research nurses’
use of time. While competing research nurse priorities
for four studies might lead to a small decrease in daily
recruitment for any single study, it allows for significant
extension of the overall recruitment period. For the
purposes of the iPCT project, this allows for more efficient capture of conditions with seasonal variation (eg,
bronchiolitis, gastroenteritis and fractures). Furthermore,
this staffing pattern alleviates the need to intermittently
relieve research staff of their duties in low prevalence
seasons, which can be highly disruptive and discourages
the retention of highly skilled staff. Finally, study teams
can share training costs, site visit coordination, data platforms, statistical support and equipment such as tablets
for data collection. Initiating four distinct trials over
Kelly LE, et al. BMJ Open 2019;9:e029024. doi:10.1136/bmjopen-2019-029024

a short period requires tremendous cooperation and
understanding among principal investigators and trial
managers. This is an existing strength within the PERC
network, and leveraging this strength is not only helping
to achieve the goals of our iPCT project, but it is also
something we hope can be passed along to researchers
outside of paediatric emergency medicine through the
continuing work of KidsCAN Trials.
Long-term sustainability
As mentioned in the Introduction, we leveraged existing
research infrastructure (including clinical trial experience and human resources) at the participating institutions to build the centralised management structures and
processes described above. Because these trials originated
from PERC investigators, the infrastructure is specific to
paediatric emergency departments. The long-term goal
of KidsCAN Trials is to use the structures and processes
emerging from the iPCT project to launch sustainable
infrastructure to support paediatric clinical trials across
all aspects of paediatric medicine, including such subspecialties as neurology, endocrinology, metabolics and
many others. These structures comprise, by necessity, a
coordinated network of core supports hosted at multiple
academic institutions or research institutes across Canada.
Figure 1 illustrates how the iPCT workflow is intended to
build these structures.
Existing networks in other North American and European countries have given us examples to follow (see box 1
for web links). In the USA, the Paediatric Trials Network
is an alliance of cooperating clinical research sites sponsored by the Eunice Kennedy Shriver National Institute of
Child Health and Human Development and is built on a
centralised hub and spoke model. In contrast, and more
aligned with our model, the Institute for Advanced Clinical Trials for Children (also in the USA) supports and
manages a network of trial-ready sites and collaborates
with disease-focused or regional research networks. Similarly, the UK Clinical Research Collaboration oversees
and supports a network of registered clinical trial units,
some of which house expertise in paediatric clinical trials.
Each of the clinical trial units is capable of independently
supporting all aspects of the clinical trial, or they have
formalised relationships with other groups to meet all trial
requirements. Other European countries have similar,
coordinated networks of multiple academic institutions or
research institutes with government-funded, core support
(eg, the Medicines for Children Research Network in the
Netherlands, the Finnish Investigators Network for Paediatric Medicines). Our objective is to learn both from these
networks and from our national iPCT experience, building
also on the experience and expertise of PERC, to grow
KidsCAN Trials into a national and sustainable resource
to coordinate and streamline paediatric clinical trials in
Canada and internationally.
Centralised risk-based safety monitoring
According to Health Canada’s interpretation on Good
Clinical Practice (GCP) (see Related Links), the purpose
5
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Canadian institutes of health research strategy for patientoriented research
►► Innovative Clinical Trials Initiative http://www.cihr-irsc.gc.ca/e/

49773.html
Engagement Framework http://www.cihr-irsc.gc.ca/e/
48413.html

►► Patient

Partners in the iPCT project
►► Maternal, Infant, Child and Youth Research Network (MICYRN) http://

micyrn.c a/
►► KidsCAN Trials https://www.kidscantrials.ca/
►► Paediatric Emergency Research Canada (PERC) https://www.perc-

canada.ca/
►► Translating Emergency Knowledge for Kids (TREKK) https://trekk.ca/
►► Children’s Hospital Research Institute of Manitoba (CHRIM) http://

chrim.ca/
►► George and Fay Yee Centre for Healthcare Innovation (CHI) https://

chimb.ca/
►► Women and Children’s Health Research Institute (WCHRI) https://

www.wchri.org/
►► The Hospital for Sick Children (SickKids) Research Institute http://

www.sickkids.ca/R
 esearch/index.h tml
►► Clinical Trials Ontario (CTO) http://www.ctontario.ca/

Web links for related networks
►► Paediatric Trials Network (PTN) https://www.pediatrictrials.org
►► Institute for Advanced Clinical Trials for Children (I-ACT) https://

www.iactc.org
►► UK Clinical Research Collaboration (UKCRC) http://www.ukcrc.org/
►► Medicines for Children Research Network (MCRN) mcrn.nl/

about-mcrn
►► Finnish Investigators Network for Paediatric Medicines (FINPEDMED)

www.finpedmed.fi
►► Generation R: Young people improving health through research in

the UK https://generationr.org.uk/
►► International Children’s Advisory Network (iCAN) https://icanre-

search.org/

Guideline documents and resources
►► Health Canada Guidance Document: Good Clinical Practice https://

www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/
alt_formats/pdf/prodpharma/applic-demande/guide-ld/ich/efficac/
e6r2-step4-eng.pdf
►► European Medicines Agency reflection paper on risk based quality management in clinical trials http://www.ema.europa.eu/
docs/en_GB/document_library/Scientific_guideline/2013/11/
WC500155491.pdf
►► Canadian Recommendations on Patient Engagement Compensation
https://diabetesaction.ca/wp-content/uploads/2018/07/TASKFORCE-IN-PATIENT-ENGAGEMENT-COMPENSATION-REPORT_
FINAL-1.pdf
►► Patient-Centred Outcomes Research Institute (PCORI) Evaluation
Framework
3.0
https://www.pcori.org/sites/default/files/
PCORI-Evaluation-Framework-3.0.pdf

of monitoring is to ensure that (i) trial data are accurate,
complete and verifiable, (ii) the trial is being conducted
according to GCP and (iii) the rights and well-being of
human subjects are protected. The most recent iteration
of GCP (ICH E6R2) recommends that clinical trials take a
6

systematic, prioritised, risk-based approach to monitoring
with a documented rationale for the chosen strategy in
the monitoring plan. Some regulators, including the
Food and Drug Administration (FDA) in the USA and
the European Medicines Agency, do not specifically
determine clinical trial oversight for sponsors, as there is
no one-size-fits-all model (see Related Links for further
information). The FDA has outlined justification criteria
for developing a risk-based monitoring plan, which are
summarised in table 1. Along with the specific activities,
monitoring plans should also describe the frequency of
monitoring, documentation, management of non-compliance and communication of monitoring results.
For our iPCT project, we have incorporated guidance
from both Health Canada and the FDA to take a risk-based
approach to our centralised monitoring strategy. As shown
in figure 4, our strategy incorporates both centralised
data monitoring and on-site monitoring components.
On-site monitoring is performed at the recruitment sites,
while centralised data monitoring involves a remote evaluation of accumulating trial data. Centralised data monitoring carries the advantage of providing routine data
review in real time and standard checks for data consistency, completeness and accuracy across sites, but it may
not identify all risks to trial integrity such as ensuring
investigators are only enrolling participants meeting all
eligibility criteria (see FDA guidance document under
Related links for further information). We accept these
parameters based on the experience of our clinical investigators and the fact that the medications studied are, for
the most part, already used commonly to manage paediatric conditions.
Monitors are typically appointed by the sponsoring
(primary) institution. The uniqueness of the iPCT project
lies in the use of bilingual, centralised monitoring so that
the four trials, conducted in parallel at six enrolling sites
in Canada, can share monitoring resources. This allows
individual sites that do not have the existing institutional
resources to provide monitoring to be included. The
shared resource is facilitated in part by the mandate of
the University of Alberta, one of our trial sponsors, to
provide its principal investigators with monitoring across
all sites. With the help of this provision, we have recruited
independent monitors, fluent in both English and French
who will monitor all four trials in parallel, to increase the
efficiency of on-site visits. Our monitors therefore have
documented qualifications and demonstrated capabilities to ensure the trial is conducted appropriately in both
of Canada’s official languages.
Ethical review
Attaining research ethics board (REB) approvals with
any efficiency is one of the main operational challenges
for multicentre clinical trials in Canada, particularly
those that span multiple provinces. In Canada, there is
no nation-wide standardised operational guidance to the
ethical review of health research, though a call for one
has been published recently.8 Individual REBs vary in
Kelly LE, et al. BMJ Open 2019;9:e029024. doi:10.1136/bmjopen-2019-029024
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Factor

Rationale for justification

Complexity of study design

More intensive monitoring may be required for studies with adaptive designs, complex
dose titrations or multiple device placements.
Subjective endpoints may require more on-site visits to ensure consistency. Objective
endpoints (eg, death, lab values) may be more suitable for centralised data monitoring.

Types of endpoints
Clinical complexity of population

Seriously ill or vulnerable populations may require more on-site monitoring to ensure
appropriate protection.

Geography

Standards of medical practice may vary between regions. Sites with less established CT
infrastructure may require more frequent on-site monitoring.

Experience of PI and sponsor

Increased monitoring may be required on principal investigators or sponsors who lack
significant CT experience or have previously failed regulatory audits.

Electronic data capture

Centralised data monitoring can capture real-time quality metrics, such as missing data,
data errors or protocol violations to identify high-risk sites for on-site monitoring.

Safety of intervention

Tapered approach may be required with increased monitoring early on until preliminary
safety data has been reviewed.
Centralised data monitoring may be more useful for large trials with multiple sites and long
duration.

Quantity of data

CT, clinical trial; PI, principal investigator.

their approval requirements, and as a result, the ethics
approval process for national, multicentre trials is inefficient, redundant, costly and burdensome to individual
sites.4
Separate from our iPCT project, and to address these
challenges on a provincial level, the Ontario Ministry
of Economic Development and Innovation established
the not-for-profit Clinical Trials Ontario (CTO) in 2012.
CTO’s mandate, accomplished through the CTO Streamlined Research Ethics Review System, is to serve as a single
provincial ethics review for multicentre clinical trials
within the province of Ontario. It has been successful in
enhancing the efficiency and consistency of the ethical
review and approval process (see Related Links for more
information). Investigators who are submitting trials to

CTO complete a web-based standardised application form
and are provided with a CTO-approved consent template.
Applications are then reviewed by a CTO-qualified Board
of Record, and delegated reviews occur at study sites.
For the purposes of our iPCT project, we have been
able to leverage the Ontario effort at least partially. Two
of the iPCT clinical trials are led by principal investigators residing in Ontario. They have a CTO-qualified
REB and thus can serve as the Board of Record for the
iPCT trial initiated by the investigator at these Ontario
institutions. Once the trial is approved by CTO, individual REB applications are still required at participating
institutions in Ontario, but these reviews are expedited
and primarily administrative. The reciprocal agreement
between CTO-approved REBs has resulted in a consistent

Figure 4 Centralised, risk-based monitoring approach used in the iPCT project. DSMB, data safety monitoring board, GCP,
Good Clinical Practice; HC, Health Canada; iPCT, Innovation in Paediatric Clinical Trials; SAE, serious adverse event.
Kelly LE, et al. BMJ Open 2019;9:e029024. doi:10.1136/bmjopen-2019-029024
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Table 1 Risk factors to consider when justifying centralised data monitoring and on-site monitoring using a risk-based
approach to monitoring clinical trials. Source: Food and Drug Administration (see related web links for further detail)
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mature consent are still variable across sites and further
efforts for harmonisation are warranted.
Patient engagement
A central tenet of the iPCT project, as part of Canada’s
Strategy for Patient-Oriented Research, is the meaningful engagement of patients (children and youth) and
their parents and families. Meaningful engagement is
defined as active collaboration with patients and families
in the governance, priority-setting, research conduct and
dissemination of results to help ensure that the research
will be relevant, appropriate and sensitive to the realworld context of patients and caregivers.11 When applying
for funding, the iPCT project engaged a parent partner
as a ‘principal knowledge user’ on the application.
This individual is now a member of the iPCT steering
committee and provides unique insight on deliverables, such as reviewing study protocols to ensure designs
are responsive to the needs of participants.12 Steering
committee members participated in an introductory
session about patient engagement in health research,
which included instruction on creating safe spaces13 and
the different types of participatory approaches needed to
gain consensus as a group. Since then, advisors from both
the TREKK parent advisory group and the CHI patient
engagement platform have been accessed by our network
members in setting up and conducting the iPCT clinical
trials. Our parent partner will also work with the steering
committee to recruit parent partners at each of the other
recruiting sites.
The approach to recruitment and enrolment of participants in clinical trials will be one area of focus for
patient engagement. The emergency department can
be a stressful, painful and even traumatic experience for
families and participation in research may not be seen
as a priority.14 15 Philosophically, patients who are the
end-users of healthcare are the best source of information when seeking the most sensitive and effective way to
approach patients and families in the emergency department for potential enrolment in a trial.16 Recruitment
strategies and study materials for the iPCT trials are
being co-developed with patients and families to help
ensure (i) that researchers are sensitive to the realities
faced by families in the paediatric emergency department, (ii) that the language and content is accessible to
potential study participants and (iii) that questions posed
by potential participants about the study are addressed
in a way that is understandable,17 culturally sensitive and
trauma-informed.
We also understand the importance of compensating
external lay partners for their valuable contribution
and provide an honorarium for meeting participation.
Researchers in Canada are becoming increasingly aware
of the need to compensate lay partners (ie, non-academics) for any expenses incurred (eg, travel, child
care) while partnering in research decision-making (see
Related Links for more information). There is also an
increasing awareness of the value of the experiential
Kelly LE, et al. BMJ Open 2019;9:e029024. doi:10.1136/bmjopen-2019-029024
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and timelier approval process, with a consistent consent
form and letter of information across the Ontario sites.
The four recruitment sites for the iPCT project that
are located outside of the province of Ontario do not
currently have a reciprocal relationship with CTO, and
thus institution-specific REB approvals are still required
for these sites. However, at the time of writing the University of Manitoba has agreed to recognise the CTO REB
approval and will allow an expedited review in Winnipeg
(rather than a full board review). The experience gained
from our iPCT project, building on the success of the
Ontario CTO effort, will not only assist the PERC network
in conducting future research, but will also better equip
MICYRN to work towards a nationally coordinated ethics
approval effort.
Another important consideration in setting up a
multi-institutional REB approval process is assent. Assent
is sought from children who are too young to fully
comprehend the risks and benefits of participation but
old enough to follow study-related tasks. Obtaining assent
serves to empower children by allowing them to participate in the decision-making process. Most REBs require
that assent be sought through a paper document signed
by the child or adolescent following consent by the caregiver.9 The content of the assent form mirrors that of the
letter of information provided with the consent form to
caregivers but using language that is comprehensible to
preadolescent children. REBs can waive the requirement
for assent based on the intellectual capacity of the child or
the magnitude of direct benefit to participation.9 There
is no predetermined age of consent in Canada, and thus
the ability to obtain consent in a clinical research setting
is predicated on establishing that the individual can
comprehend the risks and benefits (if any) of participation. It also helps to ensure their potential concerns are
communicated to research teams.
There is currently no consensus on the ‘operational
and construct definitions’ of assent in children, nor is
there any standardised governance regarding from whom
assent should be sought. As a result, assent forms and policies are often institutionally heterogeneous and, furthermore, are easily conflated with caregiver consent.10 For
example, each of the six iPCT enrolling sites (with one
exception) had a unique REB-driven approach to the
assent form. Differences in the information contained in
assent forms across sites could theoretically pose difficulties with recruitment and compliance. To overcome this
limitation, we developed a common assent template for
the iPCT project, based on the existing institutional forms
available. The common template was then presented to
a parent focus group (provided by the TREKK network,
described under ‘Partnerships’ above) and their children,
who provided valuable insight. At the time of writing, CTO
(which has an established consent template) has the iPCT
assent template under review for potential province-wide
implementation in Ontario, which demonstrates the
influence of projects like iPCT on provincial and federal
jurisdictions. Policies surrounding the age of assent and
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Challenges and solutions
The establishment of the iPCT infrastructure was not
without obstacles. The team encountered specific
implementation challenges pertaining to budget and
Kelly LE, et al. BMJ Open 2019;9:e029024. doi:10.1136/bmjopen-2019-029024

operations. Long delays in legal negotiations were eventually resolved by a teleconference among legal representatives from all involved parties which assisted the contract
process. However, these delays in the partnership agreement carried over to the transfer of funds to participating
institutes, postponing the hiring of dedicated research
team members. Fortunately, the principal investigators for
each of the four trials were able to engage the support of
existing research staff to support protocol development.
An additional lesson learnt was in the identification of
a manufacturing process for placebo study formulation.
Several companies provided quotes which far exceeded
the initial budget estimates. Eventually, the College of
Pharmacy at the University of Manitoba was engaged to
create the oral elixir placebo formulations and complete
stability testing as required for the clinical trials application. Each site can now formulate both the active and
placebo compounds in their local pharmacy. This is
aligned with compounding which already occurs at the
involved paediatric centres. On-site formulations by experienced research pharmacies has allowed for significant
savings in both product and shipping fees, and the development of new academic partnerships.
Conclusions
Our iPCT project represents the first joint venture
between an existing specialised paediatric research
network (PERC) and a centralised clinical trial management system (KidsCAN Trials) in Canada. In this
project we are implementing innovative, cost-saving and
patient-centred operational methods to conduct multiple
clinical trials in parallel across six hospitals in four Canadian provinces. While paediatric clinical trial networks
exist in other jurisdictions such as the USA and Europe,
KidsCAN Trials is one of the first collaborations in Canada
to support multidisciplinary research in the safe and effective use of pharmaceuticals in children. We learnt a great
deal about process and operations of managing multiple
academic sponsors with regulatory quality clinical trials
across multiple jurisdictions and centres. The impact of
this collaboration on the feasibility and trial quality will
be evaluated prospectively and used (i) to assist PERC
and other paediatric research collaborations in the future
and (ii) to inform future KidsCAN Trials initiatives. We
look forward to achieving both aims and to contribute to
the international paediatric clinical research community.
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knowledge of public partners, demonstrated by the recognition of, and financial compensation for, the contribution of time, energy and expertise18 by members of the lay
public. However, guidelines in Canada on compensation
are broad, and there are different compensation regulations across the provinces, making it difficult to apply a
consistent approach. We intend for the iPCT project to
set a national example and contribute to the discussion
about standards and guidelines.
To determine the effectiveness and utility of the
proposed patient engagement strategies, a mixedmethods evaluation approach will be applied annually
as part of the iPCT project outcomes. Our approach is
modelled after various sources, including other advisory
networks such as the International Children’s Advisory
Network, the UK-based Generation R and the US-based
Patient-Centred Outcomes Research Institute. Online
surveys and one-on-one interviews with patient or parent
partners, researchers and other network members are
being designed to help inform (i) the quality of engagement activities (eg, Do patient partners feel heard and
valued? Do researchers respect the experiential knowledge
contributed by patient partners? How are disagreements
and conflicts resolved?), (ii) the level of engagement and
participatory approaches chosen (eg, Does the participatory approach that we use help us come to a consensus on
research decisions?) and (iii) the impact of engagement
(eg, on the research project, on the researchers, on the
patient partners).19 20
Parent partners have also played a pivotal role in the
study design. One of the trials in the iPCT project is using
a novel preference-informed complementary trial design.
This approach is built around two simultaneous trials to
maximise participation, optimise cost-effectiveness and
allow for a qualitative exploration of the reasons behind
caregiver decision-making. Because this novel trial design
allows for the caregivers of study participants to choose
which of two trials they wish to participate in, parent
involvement in trial and survey tool design was critical.
One parent representative has been involved from the
outset, informing the development of research methods,
case report forms and scripts for research staff who will
be approaching families for recruitment. Her presence
at team meetings, both via teleconference and in person,
allows for the application of a unique family-centred,
non-clinical lens to the planning of the study. Notably, her
insight has informed more sensitive and family-centred
wording for our surveys. A parent advisory group is also
informing the development of the qualitative portions
of the study, where we seek to understand caregiver
reasoning for medical decisions regarding drug choices.
In this manner, we are able to ensure that our results
reflect and capture what matters to families.
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